CTXR Valuation

Citius Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

1.170

-0.01(-0.847%)1D

Overview
Forecast
Valuation
Earnings

CTXR Relative Valuation

CTXR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CTXR is overvalued; if below, it's undervalued.

Historical Valuation

Citius Pharmaceuticals Inc (CTXR) is now in the Fair zone, suggesting that its current forward PS ratio of 0.40 is considered Fairly compared with the five-year average of -5.35. The fair price of Citius Pharmaceuticals Inc (CTXR) is between 1.02 to 3.09 according to relative valuation methord.

Relative Value

Fair Zone

1.02-3.09

Current Price：1.18

Fair

1.29

Trailing

Forward

0.00

EV/EBITDA

Citius Pharmaceuticals Inc. (CTXR) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-2.13

EV/EBIT

Citius Pharmaceuticals Inc. (CTXR) has a current EV/EBIT of -2.13. The 5-year average EV/EBIT is 2.82. The thresholds are as follows: Strongly Undervalued below -45.69, Undervalued between -45.69 and -21.43, Fairly Valued between 27.08 and -21.43, Overvalued between 27.08 and 51.34, and Strongly Overvalued above 51.34. The current Forward EV/EBIT of -2.13 falls within the Historic Trend Line -Fairly Valued range.

0.41

Citius Pharmaceuticals Inc. (CTXR) has a current PS of 0.41. The 5-year average PS is 4.36. The thresholds are as follows: Strongly Undervalued below -7.37, Undervalued between -7.37 and -1.51, Fairly Valued between 10.23 and -1.51, Overvalued between 10.23 and 16.09, and Strongly Overvalued above 16.09. The current Forward PS of 0.41 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Citius Pharmaceuticals Inc. (CTXR) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.29. The thresholds are as follows: Strongly Undervalued below -17.45, Undervalued between -17.45 and -8.58, Fairly Valued between 9.16 and -8.58, Overvalued between 9.16 and 18.04, and Strongly Overvalued above 18.04. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Citius Pharmaceuticals Inc. (CTXR) has a current P/FCF of 0.00. The 5-year average P/FCF is -0.30. The thresholds are as follows: Strongly Undervalued below -14.64, Undervalued between -14.64 and -7.47, Fairly Valued between 6.87 and -7.47, Overvalued between 6.87 and 14.05, and Strongly Overvalued above 14.05. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Citius Pharmaceuticals Inc (CTXR) has a current Price-to-Book (P/B) ratio of 0.26. Compared to its 3-year average P/B ratio of 1.17 , the current P/B ratio is approximately -77.55% higher. Relative to its 5-year average P/B ratio of 1.53, the current P/B ratio is about -82.89% higher. Citius Pharmaceuticals Inc (CTXR) has a Forward Free Cash Flow (FCF) yield of approximately -103.42%. Compared to its 3-year average FCF yield of -62.31%, the current FCF yield is approximately 65.96% lower. Relative to its 5-year average FCF yield of -43.04% , the current FCF yield is about 140.27% lower.

0.26

P/B

Median3y

1.17

Median5y

1.53

-102.54

FCF Yield

Median3y

-62.31

Median5y

-43.04

Competitors Valuation Multiple

The average P/S ratio for CTXR's competitors is 1.02, providing a benchmark for relative valuation. Citius Pharmaceuticals Inc Corp (CTXR) exhibits a P/S ratio of 0.41, which is -60.34% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

CTXR.O

Citius Pharmaceuticals Inc

Harvard Bioscience Inc

Performance Decomposition

Market capitalization of CTXR increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of CTXR in the past 1 year is driven by Unknown.